Paraguay Medical Device Registration 2026: Twelve-Month Abandonment, Rejection and Re-Application Rules

1. Key takeaways

1. Article 27: where a device registration application has been pending for 12 months without the applicant pursuing the procedure (sin que el solicitante inste el proceso), the application is deemed abandoned and closed as a matter of law (abandonados y finiquitados de puro derecho). No discretionary decision is required for the closure to take effect.
2. Article 26: where an application has been rejected, the interested party may apply for registration again, provided the corresponding fee is paid and the requirements of the resolution are met. The re-application is a full new assessment, not a resumption of the old file.
3. A late deficiency response likewise leads to rejection: failure to complete the requested items within 60 working days, or an unsatisfactory outcome of the technical assessment, results in rejection of the application (Article 9). A second, shorter window of 30 working days applies to the follow-up deficiency stage.
4. The three numbers form a complete closed loop: 60 / 30 working days for deficiency responses → 12-month abandonment → re-application requires a new fee. Every stage of the timeline ends either in progress or in a payment event.

2. Legal basis

These three provisions allocate time risk to the applicant side of the procedure: Article 9 disciplines the deficiency stage, Article 27 closes files that stall, and Article 26 prices the restart. Together they make applicant inactivity the single most controllable cause of lost timelines and lost money.

The record-keeping consequence of the abandonment rule is easy to overlook. Because the trigger is the applicant failing to pursue the procedure, evidence of pursuit — submitted responses, correspondence, and filings on the record — is what separates a progressing file from a dormant one in a retrospective dispute. A company that works on the file internally but never transmits anything to the authority accumulates no such evidence. Regulatory owners should therefore ensure that every meaningful step in the preparation of a response is transmitted to DINAVISA within the applicable window rather than held back for perfection, and that acknowledgment of receipt is preserved in the project file alongside the internal tracker.

3. Expert insights

Insight one: the 12-month abandonment rule targets inaction by the applicant. The wording of the provision is inste el proceso — pursue the procedure — and not a failure of DINAVISA to complete its review. The rule disciplines the company side: deficiency responses left unanswered and documents left uncompleted cause the file to be closed automatically, and the closure is not reversible. Companies that experience an internal reorganization or a change of local partner during an ongoing application are especially exposed, because ownership of the pending file often lapses precisely during those transitions.

Insight two: abandonment and rejection have different legal characters but similar practical remedies. After a rejection, Article 26 provides an explicit re-application route (pay the fee and apply again); abandonment occurs de puro derecho — automatically by operation of law. In practice an abandoned file likewise requires a new application and a new fee, but its cause is attributable to the applicant itself (practical estimate: an inference drawn from the wording of the provisions). The distinction matters for internal accountability: an abandonment is a self-inflicted event, and boards should treat it as such.

Insight three: the 12 months and the 120 working days create double time pressure. The statutory assessment timeline for the comprehensive analysis pathway is 120 working days; if two rounds of deficiency responses are added (60 plus 30 working days), the time consumed on the company side is already substantial. Add translation, legalization, and other upstream preparation, and the file can approach the 12-month line without anyone noticing. The project schedule must draw this line explicitly and monitor the cumulative elapsed time, not just the individual response deadlines.

Insight four: the closed loop changes how launch dates should be set. Because inactivity ends the file at 12 months and every restart costs a new fee, the commercial launch plan must be built on the regulatory calendar rather than the other way around. Marketing teams that fix a launch date first push the regulatory team into compressed response windows, which raises the probability of rejection and with it the probability of a second fee under Article 26. Reversing the sequence — deriving the launch date from the realistic assessment timeline plus response buffers — is the only configuration in which the 60, 30, and 120 working day numbers work in the company’s favor.

4. Practical recommendations

1. Mark the 12-month red line from the submission date explicitly in the project schedule, with an early warning set well before it.
2. Answer the deficiency request in full within the 60 working days, avoiding activation of the second 30-working-day window.
3. Where materials genuinely require a long time to complete (for example, certificate exchange abroad), evaluate the cost difference between withdrawing and re-filing versus carrying the file to abandonment.
4. Include the fee for a re-application after rejection in the budget, so the Article 26 route is fundable without delay.
5. Name a backup owner for each pending file, so that absences, handovers, or partner changes never leave an active application without someone responsible for pushing it within the statutory windows.
6. Report the elapsed-time status of every pending application to management on a fixed monthly cycle, so the approach toward the 12-month line is visible long before it becomes critical.

5. Verification checklist

• □ 12-month abandonment red line marked in the schedule
• □ Deficiency response planned against the 60-working-day window
• □ Cost difference between withdrawal and re-filing versus abandonment evaluated
• □ Budget includes the re-application fee under Article 26
• □ Complete record of file progression retained (evidence that the procedure was pursued)

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Paraguay for manufacturers, importers, and authorized representatives, covering timeline management, deficiency responses, and re-application strategy. Contact info@grzanglobal.com for tailored guidance on this topic.